ArticleThe FEBS journal2021

Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.

Mei-Kuang ChenPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.